Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasting-Mimicking Diet Combined With Toripalimab Plus Axitinib for Metastatic or Unresectable Renal Cell Carcinoma
NCT07500831Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial in renal cell carcinoma (RCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Incidence and Severity of Adverse Events. Planned start Apr 2026; status: not yet recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07500831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500831.